{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:25:34Z","timestamp":1772119534933,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1 TR 001871"],"award-info":[{"award-number":["TL1 TR 001871"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA256047"],"award-info":[{"award-number":["K08CA256047"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Primary site surgery for metastatic breast cancer improves local control but does not impact overall survival. Whether histologic subtype influences patient selection for surgery is unknown. Given differences in surgical management between early-stage lobular versus ductal disease, we evaluated the impact of histology on primary site surgery in patients with metastatic breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The National Cancer Database (NCDB, 2010\u20132016) was queried for patients with stage IV HR-positive, HER2-negative invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). We compared clinicopathologic features, primary site surgery rates, and outcomes by histologic subtype. Multivariable Cox proportional hazard models with and without propensity score matching were used for overall survival (OS) analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 25,294 patients, primary site surgery was slightly but significantly less common in the 6,123 patients with ILC compared to the 19,171 patients with IDC (26.9% versus 28.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004). Those with ILC were less likely to receive chemotherapy (41.3% versus 47.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) or radiotherapy (29.1% versus 37.9%,\n                      <jats:italic>p\u2009&lt;<\/jats:italic>\n                      \u20090.0001), and had shorter OS. While mastectomy rates were similar, those with ILC who underwent lumpectomy had significantly higher positive margin rates (ILC 15.7% versus IDC 11.2%,\n                      <jats:italic>p\u2009=<\/jats:italic>\n                      \u20090.025). In both groups, the odds of undergoing surgery decreased over time, and were higher in younger patients with T2\/T3 tumors and higher nodal burden.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lobular histology is associated with less primary site surgery, higher positive margin rates, less radiotherapy and chemotherapy, and shorter OS compared to those with HR-positive HER2-negative IDC. These findings support the need for ILC-specific data and treatment approaches in the setting of metastatic disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-023-07125-5","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T12:01:43Z","timestamp":1697198503000},"page":"245-256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB)"],"prefix":"10.1007","volume":"203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5311-2872","authenticated-orcid":false,"given":"Harriet T","family":"Rothschild","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1439-0532","authenticated-orcid":false,"given":"Elle N","family":"Clelland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0447-5823","authenticated-orcid":false,"given":"Mary Kathryn","family":"Abel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2978-6249","authenticated-orcid":false,"given":"A Jo","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy M","family":"Shui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9202-4568","authenticated-orcid":false,"given":"Laura","family":"Esserman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6307-2023","authenticated-orcid":false,"given":"Seema A","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8079-7846","authenticated-orcid":false,"given":"Rita A","family":"Mukhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"7125_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13058-015-0546-7","volume":"17","author":"L Dossus","year":"2015","unstructured":"Dossus L, Benusiglio PR (2015) Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Res 17:37. https:\/\/doi.org\/10.1186\/s13058-015-0546-7","journal-title":"Breast Cancer Res"},{"key":"7125_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1055\/s-0043-109374","volume":"77","author":"A Mathew","year":"2017","unstructured":"Mathew A, Rajagopal PS, Villgran V et al (2017) Distinct pattern of Metastases in patients with invasive lobular carcinoma of the breast. Geburtshilfe Frauenheilkd 77:660\u2013666. https:\/\/doi.org\/10.1055\/s-0043-109374","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"7125_CR3","doi-asserted-by":"publisher","first-page":"R149","DOI":"10.1186\/bcr767","volume":"6","author":"G Arpino","year":"2004","unstructured":"Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6:R149. https:\/\/doi.org\/10.1186\/bcr767","journal-title":"Breast Cancer Res"},{"key":"7125_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2021.12.036","author":"MS Sun","year":"2022","unstructured":"Sun MS, Yan HC, Gao M, Liu HJ, Xu L (2022) De novo metastatic lobular breast carcinoma: a population-based study from SEER database. Asian J Surg. https:\/\/doi.org\/10.1016\/j.asjsur.2021.12.036","journal-title":"Asian J Surg"},{"key":"7125_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12885-016-2275-4","volume":"16","author":"Y Adachi","year":"2016","unstructured":"Adachi Y, Ishiguro J, Kotani H et al (2016) Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. BMC Cancer 16:248. https:\/\/doi.org\/10.1186\/s12885-016-2275-4","journal-title":"BMC Cancer"},{"key":"7125_CR6","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/cncr.23811","volume":"113","author":"E Orvieto","year":"2008","unstructured":"Orvieto E, Maiorano E, Bottiglieri L et al (2008) Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single Institution. Cancer 113:1511\u20131520. https:\/\/doi.org\/10.1002\/cncr.23811","journal-title":"Cancer"},{"key":"7125_CR7","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.1245\/s10434-007-9547-9","volume":"14","author":"SA Khan","year":"2007","unstructured":"Khan SA (2007) Primary tumor resection in stage IV breast Cancer: consistent benefit, or consistent Bias? Ann Surg Oncol 14:3285\u20133287. https:\/\/doi.org\/10.1245\/s10434-007-9547-9","journal-title":"Ann Surg Oncol"},{"key":"7125_CR8","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1245\/s10434-007-9438-0","volume":"14","author":"J Gnerlich","year":"2007","unstructured":"Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA (2007) Surgical removal of the primary tumor increases overall survival in patients with metastatic breast Cancer: analysis of the 1988\u20132003 SEER Data. Ann Surg Oncol 14:2187\u20132194. https:\/\/doi.org\/10.1245\/s10434-007-9438-0","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"7125_CR9","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1200\/JCO.21.02006","volume":"40","author":"SA Khan","year":"2022","unstructured":"Khan SA, Zhao F, Goldstein LJ et al (2022) Early local therapy for the primary site in De Novo Stage IV breast Cancer: results of a Randomized Clinical Trial (E2108). J Clin Oncol 40(9):978\u2013987. https:\/\/doi.org\/10.1200\/JCO.21.02006","journal-title":"J Clin Oncol"},{"key":"7125_CR10","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1245\/s10434-018-6494-6","volume":"25","author":"A Soran","year":"2018","unstructured":"Soran A, Ozmen V, Ozbas S et al (2018) Randomized trial comparing resection of primary tumor with no surgery in stage IV breast Cancer at Presentation: protocol MF07-01. Ann Surg Oncol 25:3141\u20133149. https:\/\/doi.org\/10.1245\/s10434-018-6494-6","journal-title":"Ann Surg Oncol"},{"key":"7125_CR11","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","volume":"16","author":"R Badwe","year":"2015","unstructured":"Badwe R, Hawaldar R, Nair N et al (2015) Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol 16:1380\u20131388. https:\/\/doi.org\/10.1016\/S1470-2045(15)00135-7","journal-title":"Lancet Oncol"},{"key":"7125_CR12","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1245\/s10434-007-9527-0","volume":"14","author":"RC Fields","year":"2007","unstructured":"Fields RC, Jeffe DB, Trinkaus K et al (2007) Surgical Resection of the primary tumor is Associated with increased long-term survival in patients with stage IV breast Cancer after Controlling for Site of Metastasis. Ann Surg Oncol 14:3345\u20133351. https:\/\/doi.org\/10.1245\/s10434-007-9527-0","journal-title":"Ann Surg Oncol"},{"key":"7125_CR13","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1002\/cncr.24873","volume":"116","author":"HB Neuman","year":"2010","unstructured":"Neuman HB, Morrogh M, Gonen M, Van Zee KJ, Morrow M, King TA (2010) Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter? Cancer 116:1226\u20131233. https:\/\/doi.org\/10.1002\/cncr.24873","journal-title":"Cancer"},{"key":"7125_CR14","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1200\/JCO.2008.21.7018","volume":"27","author":"KY Bilimoria","year":"2009","unstructured":"Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY (2009) Comparison of commission on Cancer\u2013approved and \u2013Nonapproved Hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol 27:4177\u20134181. https:\/\/doi.org\/10.1200\/JCO.2008.21.7018","journal-title":"J Clin Oncol"},{"key":"7125_CR15","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","volume":"3","author":"DJ Boffa","year":"2017","unstructured":"Boffa DJ, Rosen JE, Mallin K et al (2017) Using the National Cancer Database for Outcomes Research: a review. JAMA Oncol 3:1722. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6905","journal-title":"JAMA Oncol"},{"key":"7125_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000521097","volume":"17","author":"Y Luo","year":"2021","unstructured":"Luo Y, Ma A, Huang S, Yu Y (2021) Invasive lobular carcinoma has worse outcome compared with invasive ductal carcinoma in stage IV breast Cancer with bone-only metastasis. Breast Care 17:296\u2013305. https:\/\/doi.org\/10.1159\/000521097","journal-title":"Breast Care"},{"key":"7125_CR17","doi-asserted-by":"publisher","first-page":"590643","DOI":"10.3389\/fonc.2020.590643","volume":"10","author":"C Yang","year":"2020","unstructured":"Yang C, Lei C, Zhang Y et al (2020) Comparison of overall survival between invasive lobular breast carcinoma and invasive ductal breast carcinoma: a propensity score matching study based on SEER Database. Front Oncol 10:590643. https:\/\/doi.org\/10.3389\/fonc.2020.590643","journal-title":"Front Oncol"},{"key":"7125_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10549-022-06572-w","volume":"193","author":"JA Mouabbi","year":"2022","unstructured":"Mouabbi JA, Hassan A, Lim B, Hortobagyi GN, Tripathy D, Layman RM (2022) Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat 193:253\u2013264. https:\/\/doi.org\/10.1007\/s10549-022-06572-w","journal-title":"Breast Cancer Res Treat"},{"key":"7125_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/1758834016644156","volume":"8","author":"R Barroso-Sousa","year":"2016","unstructured":"Barroso-Sousa R, Metzger-Filho O (2016) Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications. Ther Adv Med Oncol 8:261\u2013266. https:\/\/doi.org\/10.1177\/1758834016644156","journal-title":"Ther Adv Med Oncol"},{"key":"7125_CR20","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1634\/theoncologist.2018-0182","volume":"24","author":"J P\u00e9rez-Garcia","year":"2019","unstructured":"P\u00e9rez-Garcia J, Cort\u00e9s J, Metzger Filho O (2019) Efficacy of Single-Agent Chemotherapy for patients with Advanced Invasive Lobular Carcinoma: a pooled analysis from three clinical trials. Oncologist 24:1041\u20131047. https:\/\/doi.org\/10.1634\/theoncologist.2018-0182","journal-title":"Oncologist"},{"key":"7125_CR21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","volume":"21","author":"JJ Gao","year":"2020","unstructured":"Gao JJ, Cheng J, Bloomquist E et al (2020) CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol 21:250\u2013260. https:\/\/doi.org\/10.1016\/S1470-2045(19)30804-6","journal-title":"Lancet Oncol"},{"key":"7125_CR22","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1200\/JCO.2007.14.9336","volume":"26","author":"BC Pestalozzi","year":"2008","unstructured":"Pestalozzi BC, Zahrieh D, Mallon E et al (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast Cancer Study Group clinical trials. J Clin Oncol 26:3006\u20133014. https:\/\/doi.org\/10.1200\/JCO.2007.14.9336","journal-title":"J Clin Oncol"},{"key":"7125_CR23","doi-asserted-by":"publisher","first-page":"591399","DOI":"10.3389\/fonc.2020.591399","volume":"10","author":"N Wilson","year":"2021","unstructured":"Wilson N, Ironside A, Diana A, Oikonomidou O (2021) Lobular breast Cancer: a review. Front Oncol 10:591399. https:\/\/doi.org\/10.3389\/fonc.2020.591399","journal-title":"Front Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07125-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-07125-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07125-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T14:04:11Z","timestamp":1705154651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-07125-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["7125"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-07125-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3137103\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"5 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the de-identified nature of the public-access user files in the National Cancer Database, the study was deemed exempt from institutional review board approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}